共 48 条
Regulation of TRAIL receptor expression by β-catenin in colorectal tumours
被引:14
作者:
Jalving, M.
[1
]
Heijink, D. M.
[1
,2
]
Koornstra, J. J.
[2
]
Boersma-van Ek, W.
[1
]
Zwart, N.
[1
]
Wesseling, J.
[3
]
Sluiter, W. J.
[4
]
de Vries, E. G. E.
[1
]
Kleibeuker, J. H.
[2
]
de Jong, S.
[1
]
机构:
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
[3] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands
关键词:
APOPTOSIS-INDUCING LIGAND;
COLON-CANCER;
DEATH RECEPTOR;
TARGET GENES;
CELL-LINES;
PATHWAY;
ADENOMAS;
MYC;
CHEMOPREVENTION;
PROLIFERATION;
D O I:
10.1093/carcin/bgt484
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Expression of the pro-apoptotic TRAIL receptors is regulated, at least in part, by beta-catenin. We show that beta-catenin co-localizes with DR4/5 in human and mouse colorectal tumours and that downregulation of beta-catenin in cell line models reduces TRAIL receptor expression and TRAIL sensitivity.Tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) is being investigated as a targeted cancer therapeutic and the expression of its pro-apoptotic receptors, DR4 and DR5, increases during colorectal carcinogenesis. This study investigated the role of beta-catenin in the regulation of these receptors. In human colorectal adenoma and carcinoma cell lines, downregulation of beta-catenin resulted in lower total DR4 and DR5 protein levels. Similarly, cell membrane expression of DR4 and DR5 was reduced after downregulation of beta-catenin in colon carcinoma cells, whereas induction of beta-catenin in HeLa cells led to increased cell membrane expression of DR4 and DR5. Downregulation of beta-catenin decreased the recombinant human TRAIL sensitivity of human colon carcinoma cells. Activation of the transcription factor T-cell factor-4 (TCF-4) is an important function of beta-catenin. Dominant-negative TCF-4 overexpression, however, did not significantly affect TRAIL receptor expression or recombinant human TRAIL sensitivity. Human colorectal adenomas (N = 158) with aberrant (cytoplasmic and nuclear) beta-catenin expression had a higher percentage of immunohistochemical DR4 and DR5 staining per tumour (mean: 73 and 88%, respectively) than those with membranous beta-catenin staining only (mean: 50 and 70%, respectively, P < 0.01 for both). Furthermore, aberrant beta-catenin staining co-localized with DR4 and DR5 expression in 92% of adenomas. In 53 human colorectal carcinomas, aberrant beta-catenin expression was present in most cases and DR4/5 expression was largely homogenous. Similarly, in adenomas from APC(min) mice, cytoplasmic beta-catenin staining co-localized with staining for the murine TRAIL death receptor. In conclusion, the gradual increase in TRAIL receptor expression during colorectal carcinogenesis is at least partially mediated through increased beta-catenin expression, independently of TCF-4-signalling.
引用
收藏
页码:1092 / 1099
页数:8
相关论文